| Protective autophagy elicited by RAF→ MEK→ ERK inhibition suggests a treatment strategy for RAS-driven cancers CG Kinsey, SA Camolotto, AM Boespflug, KP Guillen, M Foth, A Truong, ... Nature medicine 25 (4), 620-627, 2019 | 616 | 2019 |
| A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology KP Guillen, M Fujita, AJ Butterfield, SD Scherer, MH Bailey, Z Chu, ... Nature cancer 3 (2), 232-250, 2022 | 243 | 2022 |
| Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor α in endometrial cancer JM Vahrenkamp, CH Yang, AC Rodriguez, A Almomen, KC Berrett, ... Cell reports 22 (11), 2995-3005, 2018 | 76 | 2018 |
| ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells AC Rodriguez, JM Vahrenkamp, KC Berrett, KA Clark, KP Guillen, ... Cancer research 80 (6), 1234-1245, 2020 | 61 | 2020 |
| PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer TH Truong, EA Benner, KM Hagen, NA Temiz, CP Kerkvliet, Y Wang, ... Oncogene 40 (25), 4384-4397, 2021 | 27 | 2021 |
| STAT3 and GR cooperate to drive gene expression and growth of basal-like triple-negative breast cancer ME Conway, JM McDaniel, JM Graham, KP Guillen, PG Oliver, SL Parker, ... Cancer research 80 (20), 4355-4370, 2020 | 23 | 2020 |
| Targeted enzyme prodrug therapy for metastatic prostate cancer–a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase KP Guillen, C Kurkjian, RG Harrison Journal of biomedical science 21, 1-8, 2014 | 23 | 2014 |
| A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology KP Guillen, M Fujita, AJ Butterfield, SD Scherer, MH Bailey, Z Chu, ... bioRxiv, 2021.02. 28.433268, 2021 | 20 | 2021 |
| A cancer-selective zinc ionophore inspired by the natural product naamidine A RM Vaden, KP Guillen, JM Salvant, CB Santiago, JB Gibbons, SS Pathi, ... ACS chemical biology 14 (1), 106-117, 2018 | 16 | 2018 |
| Annexin-directed β-glucuronidase for the targeted treatment of solid tumors KP Guillen, EA Ruben, N Virani, RG Harrison Protein Engineering, Design and Selection 30 (2), 85-94, 2017 | 14 | 2017 |
| Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential D Drobysheva, BA Smith, M McDowell, KP Guillen, HA Ekiz, BE Welm Breast Cancer Research 17, 1-17, 2015 | 14 | 2015 |
| Protein synthesis inhibitors stimulate MondoA transcriptional activity by driving an accumulation of glucose 6-phosphate BR Wilde, MR Kaadige, KP Guillen, A Butterfield, BE Welm, DE Ayer Cancer & metabolism 8, 1-13, 2020 | 12 | 2020 |
| Breast cancer PDxO cultures for drug discovery and functional precision oncology SD Scherer, L Zhao, AJ Butterfield, CH Yang, E Cortes-Sanchez, ... STAR protocols 4 (3), 102402, 2023 | 8 | 2023 |
| Annexin V-Directed enzyme prodrug therapy plus docetaxel for the targeted treatment of pancreatic cancer KP Guillen, A Restuccia, C Kurkjian, RG Harrison Pancreas 44 (6), 945-952, 2015 | 6 | 2015 |
| Abstract LB-254: Combined inhibition of MEK and autophagy promotes regression of pancreatic cancer C Kinsey, K Guillen, S Camolotto, A Boespflug, J Shea, M Seipp, C Scaife, ... Cancer Research 78 (13_Supplement), LB-254-LB-254, 2018 | 2 | 2018 |
| Elephant p53 (EP53) expression induces apoptosis of human cancer cells LM Abegglen, LN Donovan, G Couldwell, R Robinson, C Toruno, ... Cancer Research 77 (13_Supplement), 2153-2153, 2017 | 2 | 2017 |
| Publisher Correction: Protective autophagy elicited by RAF [right arrow] MEK [right arrow] ERK inhibition suggests a treatment strategy for RAS-driven cancers CG Kinsey, SA Camolotto, AM Boespflug, KP Guillen, M Foth, A Truong, ... Nature Medicine 25 (5), 861-862, 2019 | 1 | 2019 |
| DNA methylation density analysis via fluorescent dye incorporation BP Keeley, VJ Bailey, C Yin, K Passlack, A Stark, HE Carraway, SB Baylin, ... Clinical Cancer Research 16 (19_Supplement), A9-A9, 2010 | 1 | 2010 |
| Compositions and methods comprising substituted 2-aminoimidazoles RE Looper, JM Salvant, EK Kirkeby, W Guo, KP Guillen, BE Welm US Patent App. 17/741,366, 2022 | | 2022 |
| Compositions and methods comprising substituted 2-aminoimidazoles RE Looper, JM Salvant, EK Kirkeby, W Guo, KP Guillen, BE Welm US Patent 11,339,140, 2022 | | 2022 |
H. Atakan EkizIzmir Institute of TechnologyVerified email at iyte.edu.tr